CNTA (Centessa Pharmaceuticals) Float Percentage Of Total Shares Outstanding: 85.03% (As of Jul. 16, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CNTA Centessa Pharmaceuticals PLC CNTA
12 GF Score
Price $40.50
! 4 Warning Signs
View Full Analysis

What is Centessa Pharmaceuticals Float Percentage Of Total Shares Outstanding?

Centessa Pharmaceuticals CNTA 12 Float Percentage Of Total Shares Outstanding is 85.03% as of Jul. 16, 2026. GuruFocus rates CNTA with a GF Score™ of 12/100. The stock has 4 warning signs investors should review.

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Centessa Pharmaceuticals's float shares is 131.57 Mil. Centessa Pharmaceuticals's total shares outstanding is 154.73 Mil. Centessa Pharmaceuticals's float percentage of total shares outstanding is 85.03%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Centessa Pharmaceuticals's Insider Ownership is 2.28%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Centessa Pharmaceuticals's Institutional Ownership is 96.06%.

CNTA
12GF Score
Centessa Pharmaceuticals PLC CNTA
Float Percentage Of Total Shares Outstanding is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Centessa Pharmaceuticals Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Centessa Pharmaceuticals's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=131.57/154.73
=85.03%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Float Percentage Of Total Shares Outstanding of 85.03% mean?
Centessa Pharmaceuticals (CNTA) has a Float Percentage Of Total Shares Outstanding of 85.03% as of Jul. 16, 2026. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Centessa Pharmaceuticals and its competitors.
Is Centessa Pharmaceuticals' Float Percentage Of Total Shares Outstanding too high?
Centessa Pharmaceuticals' current Float Percentage Of Total Shares Outstanding is 85.03%. Overall, Centessa Pharmaceuticals has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Centessa Pharmaceuticals' Float Percentage Of Total Shares Outstanding compare to CGON and LGND?
Centessa Pharmaceuticals' Float Percentage Of Total Shares Outstanding of 85.03% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Float Percentage Of Total Shares Outstanding for a Biotechnology company?
A good Float Percentage Of Total Shares Outstanding depends on the Biotechnology industry context. However, Float Percentage Of Total Shares Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Float Percentage Of Total Shares Outstanding mean?
A high Float Percentage Of Total Shares Outstanding can signal that a stock is expensive relative to its fundamentals. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Centessa Pharmaceuticals and its competitors. Centessa Pharmaceuticals's current Float Percentage Of Total Shares Outstanding is 85.03%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Centessa Pharmaceuticals stock overvalued right now?
Centessa Pharmaceuticals (CNTA) has a current Float Percentage Of Total Shares Outstanding of 85.03%. The current Float Percentage Of Total Shares Outstanding is 85.03%. Centessa Pharmaceuticals' overall GF Score™ is 12/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Float Percentage Of Total Shares Outstanding calculated?
Float Percentage Of Total Shares Outstanding is calculated from a company's financial statements. For Centessa Pharmaceuticals (CNTA), the current Float Percentage Of Total Shares Outstanding is 85.03% as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Centessa Pharmaceuticals Business Description

Other Exchanges 0ACX:UK260:Germany
Address 1 Ashley Road, 3rd Floor, Altrincham, Cheshire, GBR, WA14 2DT
Centessa Pharmaceuticals PLC is a clinical-stage biotechnology company pioneering a new class of therapeutics in orexin-based neuroscience. The group is developing a franchise of small molecule orexin receptor 2 (OX2R) agonists designed to address neuroscience diseases underpinned by dysregulation of wakefulness, attention, cognition, mood, and other symptoms, each grounded in the shared biology of the orexin pathway. The company's programs and Pipeline are the Orexin Receptor 2 Agonist Program and LockBody Technology Platform.
12GF Score

Get the complete analysis for CNTA

Float Percentage Of Total Shares Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$40.50
Price